Plasmodium Vivax
12
1
2
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
75.0%
-11.5% vs benchmark
42%
5 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
Vivax Elimination With Tafenoquine (VET) Study
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Phenotyping and Genotyping of Duffy Antigen
The Malaria Heart Disease Study
P.Vivax Treatment Trial
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
Phase Ia Study of ChAd63/MVA PvDBP
Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam
Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection